GGrantIndex
← Leaderboards

Susan H Eshleman

Johns Hopkins University

$103,346,426
Attributed
$117,988,948
Total exposure
7
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $14.8M · FY200525
$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$117,988,948 · 7

By mechanism

UM1$91,183,797 · 1
U01$16,539,477 · 1
R01$9,989,444 · 3
R03$163,180 · 1
R29$113,050 · 1

Top collaborators

Most similar at Johns Hopkins University

Same institution · by research overlap

Others in their field

Top investigators on “Aids Prevention

Research focus

Aids PreventionDesignHiv InfectionsPreventionLaboratoriesAfricaTransmission ProcessAnti-Retroviral AgentsPerformanceHiv Prevention Trials NetworkPharmaceutical PreparationsCommunitiesAfrica South Of The SaharaSamplingAsiaPrevention ResearchPrevention StrategyPopulations At RiskBehavioralLeadershipMen Who Have Sex With MenInternationalMissionSite

Grant awards (43)

LC: HIV PREVENTION TRIALS NETWORK$8,531,038
UM1 · FY2025 · AI · contact PI
LC: HIV PREVENTION TRIALS NETWORK$4,024,293
UM1 · FY2024 · AI · contact PI
LC: HIV PREVENTION TRIALS NETWORK$6,974,239
UM1 · FY2023 · AI · contact PI
LC: HIV PREVENTION TRIALS NETWORK$6,848,077
UM1 · FY2022 · AI · contact PI
LC: HIV PREVENTION TRIALS NETWORK$11,779,883
UM1 · FY2021 · AI · contact PI
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)$2,331,636
UM1 · FY2021 · AI · contact PI
HIV incidence testing in an evolving epidemic: Identification of accurate multi-assay algorithms that include serosignatures from a novel antibody profiling system.$695,133
R01 · FY2021 · AI · contact PI
LC: HIV Prevention Trials Network$3,027,715
UM1 · FY2020 · AI · contact PI
HIV incidence testing in an evolving epidemic: Identification of accurate multi-assay algorithms that include serosignatures from a novel antibody profiling system.$708,682
R01 · FY2020 · AI · contact PI
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)$167,145
UM1 · FY2020 · AI · contact PI
LC: HIV Prevention Trials Network$5,668,821
UM1 · FY2019 · AI · contact PI
HIV incidence testing in an evolving epidemic: Identification of accurate multi-assay algorithms that include serosignatures from a novel antibody profiling system.$727,681
R01 · FY2019 · AI · contact PI
LC: HIV Prevention Trials Network$4,349,197
UM1 · FY2018 · AI · contact PI
HIV incidence testing in an evolving epidemic: Identification of accurate multi-assay algorithms that include serosignatures from a novel antibody profiling system.$742,649
R01 · FY2018 · AI · contact PI
LC: HIV Prevention Trials Network$4,245,488
UM1 · FY2017 · AI · contact PI
HIV incidence testing in an evolving epidemic: Identification of accurate multi-assay algorithms that include serosignatures from a novel antibody profiling system.$768,641
R01 · FY2017 · AI · contact PI
LC: HIV Prevention Trials Network$5,663,547
UM1 · FY2016 · AI · contact PI
LC: HIV Prevention Trials Network$6,993,955
UM1 · FY2015 · AI · contact PI
LC: HIV Prevention Trials Network$7,306,283
UM1 · FY2014 · AI · contact PI
Laboratory and Statistical Development of Cross-Sectional HIV Incidence Assays$730,270
R01 · FY2014 · AI · contact PI
HIV Prevention Trials Network: Network Laboratory$1,777,536
UM1 · FY2013 · AI · contact PI
HIV Prevention Trials Network: Network Laboratory$1,074,961
UM1 · FY2013 · AI · contact PI
Laboratory and Statistical Development of Cross-Sectional HIV Incidence Assays$686,668
R01 · FY2013 · AI · contact PI
Impact of maternal HAART on HIV-infected breastfeeding infants: Malawi$583,897
R01 · FY2013 · AI · contact PI
HIV Prevention Trials Network: Network Laboratory$5,037,579
UM1 · FY2012 · AI · contact PI
Laboratory and Statistical Development of Cross-Sectional HIV Incidence Assays$730,497
R01 · FY2012 · AI · contact PI
Impact of maternal HAART on HIV-infected breastfeeding infants: Malawi$606,298
R01 · FY2012 · AI · contact PI
HIV Prevention Trials Network: Network Laboratory$5,382,404
UM1 · FY2011 · AI · contact PI
Laboratory and Statistical Development of Cross-Sectional HIV Incidence Assays$759,963
R01 · FY2011 · AI · contact PI
Impact of maternal HAART on HIV-infected breastfeeding infants: Malawi$607,126
R01 · FY2011 · AI · contact PI
HIV Prevention Trials Network: Network Laboratory$2,654,477
U01 · FY2010 · AI · contact PI
Impact of maternal HAART on HIV-infected breastfeeding infants: Malawi$611,887
R01 · FY2010 · AI · contact PI
Resistance in HIV-infected infants after extended ARV prophylaxis: PEPI-Malawi$81,180
R03 · FY2010 · HD · contact PI
HIV Prevention Trials Network: Network Laboratory$4,116,871
U01 · FY2009 · AI · contact PI
Resistance in HIV-infected infants after extended ARV prophylaxis: PEPI-Malawi$82,000
R03 · FY2009 · HD · contact PI
HIV Prevention Trials Network: Network Laboratory$3,273,493
U01 · FY2008 · AI · contact PI
HIV Prevention Trials Network: Network Laboratory$3,396,430
U01 · FY2007 · AI · contact PI
HIV Prevention Trials Network: Network Laboratory$3,098,206
U01 · FY2006 · AI · contact PI
Drug Resistance in Non-Subtype B HIV-1$257,513
R01 · FY2005 · HD
Drug Resistance in Non-Subtype B HIV-1$257,513
R01 · FY2004 · HD
Drug Resistance in Non-Subtype B HIV-1$257,513
R01 · FY2003 · HD
Drug Resistance in Non-Subtype B HIV-1$257,513
R01 · FY2002 · HD
V3 REGION DIVERSITY IN HIV VERTICAL TRANSMISSION: UGANDA$113,050
R29 · FY2000 · HD